New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
11:21 EDTARIA, WPX, VOLC, PVTB, PANW, IFNNY, GILD, FRX, CBST, CELG, BIIB, AMGN, ALXN, ABMD, ZLCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Guggenheim... Abiomed (ABMD) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Buy at Guggenheim... Amgen (AMGN) initiated with a Neutral at Guggenheim... Biogen (BIIB) initiated with a Neutral at Guggenheim... Celgene (CELG) initiated with a Buy at Guggenheim... Cubist (CBST) initiated with a Neutral at Mizuho... Forest Labs (FRX) initiated with a Buy at Mizuho... Gilead (GILD) initiated with a Buy at Guggenheim... Infineon (IFNNY) initiated with an Outperform at Bernstein... Palo Alto (PANW) initiated with a Neutral at BofA/Merrill... PrivateBancorp (PVTB) initiated with a Market Perform at Wells Fargo... Volcano (VOLC) initiated with an Outperform at Raymond James... WPX Energy (WPX) initiated with a Hold at Deutsche Bank... Zale (ZLC) initiated with a Buy at Citigroup.
News For ARIA;ABMD;ALXN;AMGN;BIIB;CELG;CBST;FRX;GILD;IFNNY;PANW;PVTB;VOLC;WPX;ZLC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 9, 2014
09:56 EDTWPXWPX Energy reaffirms adjusted full-year production guidance
WPX Energy reaffirmed its full-year production guidance ranges, adjusted for its Powder River sale. In the Williston, WPX says its initial result of larger stimulations encouraging. In San Juan Gallup, WPX says it is completing first two 7,500ʹ laterals and that a 3rd rig has been added. Guidance and comments from slides for strategic update.
08:28 EDTGILDGilead to be challenged by AbbVie in HCV near-term, says Bernstein
Subscribe for More Information
06:40 EDTPANWSource of JPMorgan cyberattack still unclear, NY Times says
The source of the cyberattack on JPMorgan (JPM) and other U.S. financial institutions this summer is still unclear, according to The New York Times. The hackers may have tried to hit about a dozen financial institutions , and E-Trade(ETFC) and Fidelity Investments may have been victimized in some way, the newspaper stated, citing an unnamed source who was briefed on the matter. At least five other banks, including Citigroup (C), HSBC (HBC) and Regions Financial (RF), discovered that one of the web addresses used by those who hacked JPMorgan tried to penetrate their systems, The Times quoted unnamed sources briefed on the matter as saying. Publicly traded companies in the space include Barracuda Networks (CUDA), Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC). Reference Link
06:36 EDTALXNAlexion appoints new chairman and creates Lead Independent Director position
Alexion has appointed Leonard Bell, M.D. as Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as CEO. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby has been a Director of Alexion since September 1999. Both of these appointments follow the passing of Max Link, Ph.D., who served as the Chairman of the Board of Directors of Alexion since December 2002 and as a member of the Board since the company’s inception in 1992.
October 8, 2014
16:44 EDTWPXWPX Energy outlines multi-year strategy
Subscribe for More Information
16:26 EDTGILDOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTGILDOptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
15:49 EDTGILDAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naďve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
12:12 EDTPANWPalo Alto management to meet with Oppenheimer
Meeting to be held in Canada on October 14 hosted by Oppenheimer.
10:20 EDTAMGNAmgen biosimilar franchise underappreciated, says Piper Jaffray
After Amgen announced positive Phase 3 results for its biosimilar Humira in psoriasis, Piper Jaffray said it believes that Amgen's overall pipeline is underappreciated since the company's biosimilar franchise is generally not included in consensus estimates. The firm views Amgen as a top large cap picks and reiterate its Overweight rating on the stock.
09:16 EDTAMGNAmgen's ABP 501 for psoriasis shows positive Phase 3 results
Subscribe for More Information
07:58 EDTPANWPalo Alto price target raised to $120 from $105 at Pacific Crest
Subscribe for More Information
07:52 EDTPANWPalo Alto has positive catalysts, says Wells Fargo
After meeting with Palo Alto's management, Wells Fargo thinks the company's new endpoint security product could increase its long-term revenue growth by five or six percentage points. The firm expects the company's product revenue to be boosted by an existing customer refresh cycle in 2015, and Wells is confident in the company's service revenue outlook. It raised its price target on the name to $112-$129 from $113-$120 and keeps an Outperform rating on the shares.
07:32 EDTPVTB PrivateBancorp to sell Norcross, Ga., branch to Heritage Financial
PrivateBancorp (PVTB) has agreed to sell The PrivateBank branch in Norcross, Ga., to Heritage Financial Group (HBOS). The transaction includes about $129M in deposits and $40M in loans from retail and small business banking clients. It does not impact clients associated with The PrivateBank's commercial middle market business development office in the Atlanta Financial Center. PrivateBancorp expects to record a one-time gain at closing of 3c-4c per share. The transaction is expected to close before the end of Q4.
07:31 EDTPVTBHeritage Financial to acquire Metro Atlanta branch from PrivateBank
Subscribe for More Information
07:19 EDTAMGNCBI to hold a conference
Subscribe for More Information
07:18 EDTGILD, CBSTInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:11 EDTAMGN, CELGEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
October 7, 2014
07:31 EDTCELGCelgene to present long-term efficacy and safety data on oral Otezla
Celgene International Sŕrl, a wholly-owned subsidiary of Celgene Corporation, announced that the latest research findings on OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4, in plaque psoriasis and psoriatic arthritis will be presented at the 23rd European Academy of Dermatology and Venereology Congress in Amsterdam, October 8 – 12. In total, 11 abstracts will be presented at the meeting. OTEZLA data to be presented include long-term results from Celgene’s pivotal trial, ESTEEM 2 and pooled analyses of safety and tolerability results from the ESTEEM 1 and 2 studies in patients with moderate to severe plaque psoriasis. Additional analyses will evaluate the effect of OTEZLA on pruritus, difficult-to-treat areas such as nail and scalp, and palmoplantar psoriasis, work productivity and improvements in health-related quality of life. An analysis of long-term results from the PALACE clinical trial program evaluating OTEZLA in patients with active psoriatic arthritis will also be presented at the meeting. The analysis assesses the effect of OTEZLA treatment through 52 weeks on the signs and symptoms of psoriatic arthritis, including enthesitis and dactylitis in patients with pre-existing enthesitis or dactylitis.
07:24 EDTCELG, BIIBAlliance for Regenerative Medicine
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use